1. Introduction: The First Institute of Blood Transfusion
In 1926 the world’s first research institute devoted to blood transfusion opened in Moscow. Its founder, Alexander Bogdanov — physician, philosopher, science-fiction author, and one of the original Bolsheviks — gave it an extraordinary programmatic premise: that exchanging blood between young and old organisms might restore youth itself. A century before modern heterochronic parabiosis experiments entered geroscience, Bogdanov performed exchange transfusions on himself and volunteers, treating the procedure as at once a therapy, an experiment, and the practical realisation of a philosophy he called «physiological collectivism.» His death in 1928 during one such exchange ended the program and began one of the most instructive legends in the history of longevity research.
This article separates three things: Bogdanov’s genuine scientific intuition (that circulating factors regulate systemic tissue state); the evidence he actually collected (uncontrolled testimonials); and what modern research has since demonstrated (that young circulatory factors do modulate aged tissues in mice, while crude human plasma transfer remains unproven and risky). The historical and the modern claims are related intellectually, but they are not the same claim, and conflating them is the central error to avoid.
2. Bogdanov: Revolutionary, Philosopher, and Physician
Bogdanov was born in 1873 in Sokolka, in the Grodno province of the Russian Empire, and took his party pseudonym from his political writing. A medical graduate of Kharkov University, he was a founder of the Bolshevik faction alongside Lenin, but broke with him and was expelled from the party in 1909; he later led the Proletkult movement and worked at the Communist Academy. His interests were unusually broad. In natural philosophy he proposed tectology (developed in the 1910s), a general science of organisation that is widely regarded as a forerunner of systems theory and cybernetics. In fiction he published the utopian novels Red Star (1908) and Engineer Menni, in which the inhabitants of a future socialist society routinely exchange blood to renew one another — an idea he treated not as metaphor but as foresight.
From about 1921 he devoted himself primarily to gerontology and haematology. He had long argued that the widespread adoption of blood transfusion would have a transforming effect on individuals and society, and he secured institutional support for the project from the highest levels of the Soviet state. The Institute of Blood Transfusion was formally approved in 1925 and established in 1926, with Bogdanov as its first director.
3. «Physiological Collectivism»: The Theory Behind the Transfusions
Bogdanov’s premise was that blood is not merely a transport medium but the principal organising mediator of the body, and that the viability of an organism depends on the circulation of life-sustaining elements. From this it followed, in his reasoning, that the shared blood of a collective could support and rejuvenate its members: «physiological collectivism» was at once a physiological theory and a social ideal. He described blood exchange as a partial conjugation — a biological analogy to the way single-celled organisms share material — and predicted improvements in immunity, resistance to disease, and the general restoration of the body.
The intuition that blood carries systemic signals capable of regulating tissue state is now known to be broadly correct: the circulation does transport cytokines, hormones, metabolites, and vesicular cargo that influence distant organs. What Bogdanov could not supply was the quantitative and mechanistic understanding to identify which signals mattered, how to isolate them, and how to test their effects. His program was therefore a bold and partly prescient hypothesis combined with an untested and dangerous intervention.
4. The Institute and the Experiments (1924-1928)
Bogdanov began exchange-transfusion experiments in 1924-1925, initially at home with a small group of like-minded physicians, later at the base of a private hospital. The work moved to the new institute in 1926; by April 1928 approximately 400 transfusions had been performed there. Bogdanov was his own most consistent subject. He described undergoing eleven transfusions by early 1928, five of them of roughly 900 mL, and reported that he tolerated them without reaction. Participants — reportedly including Lenin’s sister and various colleagues — described improved vigour and eyesight, and a fellow revolutionary wrote that Bogdanov appeared years younger after the procedure.
These observations are testimonial and uncontrolled. There was no comparison group, no blinding, no predefined endpoint, and no standardised measure of aging or vigour. Subjective feelings of improved wellbeing after an invasive medical procedure are well known to be influenced by expectation. The reports are historically meaningful as the first attempt to treat circulating factors as a rejuvenation target, but they are not evidence that the intervention altered aging.
5. The Fatal Transfusion of 1928
On 24 March 1928 Bogdanov performed an exchange transfusion with a 21-year-old student, L. Koldomasov, who had previously had malaria and was suffering from tuberculosis. Within roughly three hours both men developed signs of acute haemolysis and an immunological reaction. The student, whose younger organism tolerated the episode, recovered and reportedly lived for more than half a century afterwards; Bogdanov’s condition deteriorated rapidly. He continued to record his own symptoms as a physician until close to the end. He died approximately two weeks later; autopsy attributed death to acute kidney failure, described officially as uraemic poisoning from severe renal damage.
The cause of the fatal reaction has never been definitively established. Blood groups were known in 1928, but the Rh factor was not discovered until around 1940, and an Rh incompatibility between donor and recipient is one of the leading modern explanations. Others have proposed disseminated intravascular coagulation, and at least one senior Russian haematologist favoured that interpretation. Because an official investigation was carried out but its results were not published, and because Bogdanov had written a strained political letter shortly beforehand, some historians have speculated about suicide or foul play. The most defensible reading, consistent with the clinical description and with the limits of 1928 medicine, is a tragic and largely unavoidable transfusion reaction — the direct consequence of attempting a systemic intervention without the immunological knowledge to make it safe.
6. Partial Vindication: Heterochronic Parabiosis
Modern research gave Bogdanov’s core intuition substantial, if partial, support. Beginning in 2005, experiments in which the circulations of young and old mice are surgically joined (heterochronic parabiosis) showed that exposure to a young systemic environment can rejuvenate aged progenitor cells and improve function in muscle, liver, and brain. Later work implicated specific circulating factors — including signalling molecules and proteins whose identity and direction of effect remain debated — and demonstrated that some benefits may be attributable to young-derived factors while others arise from dilution of old-derived inhibitory factors.
Two features of this literature are essential for interpreting Bogdanov. First, these are mouse results establishing proof of a principle (that systemic factors modulate age-related tissue decline), not evidence that blood exchange rejuvenates humans. Second, even within mice the field is contentious: the role of growth/differentiation factor 11 (GDF11), for example, was initially reported to decline with age and to have rejuvenating effects, but subsequent studies found it to increase with age and to impair muscle regeneration, with the discrepancy attributed partly to differences in reagents and assays. The identification of causal factors — among them the protein TIMP2 and others — remains an emerging, actively debated area rather than settled science.
7. The Translation Gap: Young Plasma in Humans
The commercial attempt to translate parabiosis directly into human therapy illustrates the gap Bogdanov could not have foreseen. A private clinic in the United States offered plasma infusions from young donors as an anti-aging treatment, charging participants to take part in an uncontrolled study. In February 2019 the U.S. Food and Drug Administration issued a public statement warning that infusions of plasma from young donors had no proven clinical benefit for the conditions being marketed, while carrying real risks of infection, allergic reaction, circulatory overload, and transfusion-related injury. The statement emphasised that such use was not an established therapy and should not be offered outside appropriately designed clinical research.
The scientific conclusion is therefore asymmetric. The principle that circulating factors influence aged tissue is supported, chiefly in animal models. The intervention of transferring whole blood or plasma from young to old humans has no demonstrated anti-aging effect and carries genuine risk. The contemporary research response has been to pursue fractionated factors — identified proteins or metabolites delivered as defined agents — rather than crude whole-blood exchange, precisely to reproduce any young-plasma benefit without its hazards.
8. Assessment: A Hypothesis, Not a Therapy
- What Bogdanov got right (hypothesis, later supported in animals). Circulating factors regulate systemic tissue state; blood-borne signals can modulate age-related decline. This is now a legitimate research field.
- What Bogdanov got wrong (intervention, unproven and dangerous). That whole-blood exchange between young and old humans is a rejuvenation therapy. There is no controlled evidence for this, and the fatal 1928 transfusion showed the lethal stakes of intervening without mechanistic understanding.
- What he could not know. The immunological basis of transfusion reactions (blood groups were known; the Rh system was not), the need for controlled trials, and the distinction between a systemic signal and a therapeutic agent.
- Methodological lesson. A bold systemic hypothesis requires molecular identification and controlled testing before human application. Bogdanov performed the sequence in reverse: human application first, mechanism never.
9. Conclusion
Bogdanov’s program added no demonstrated years of life. Its value is directional and cautionary at once. It identified, a century early, that the circulation carries system-level regulators of aging — a target modern science now pursues with fractionated factors rather than whole blood. It also showed, at the cost of its founder’s life, that enthusiasm for a systemic intervention cannot substitute for the immunological and clinical knowledge required to make that intervention safe. Every contemporary study of plasma-derived rejuvenation factors descends intellectually from his institute; every such study also inherits his warning to identify the mechanism before treating the patient.
Sources and Key Research Centers
- Huestis DW. «Alexander Bogdanov: the forgotten pioneer of blood transfusion.» Transfusion Medicine Reviews, 2007; 21(4): 337-341. PMID: 17900494
- Krementsov N. A Martian Stranded on Earth: Alexander Bogdanov, Blood Transfusions, and Proletarian Science. University of Chicago Press, 2011.
- Conboy IM, Conboy MJ, Wagers AJ, Girma ER, Weissman IL, Rando TA. «Rejuvenation of aged progenitor cells by exposure to a young systemic environment.» Nature, 2005; 433(7027): 760-764. DOI: 10.1038/nature03260
- Katsimpardi L, Litterman NK, Schein PA, et al. «Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors.» Science, 2014; 344(6184): 630-634. DOI: 10.1126/science.1251141
- Castellano JM, Mosher KI, Abbey RJ, et al. «Human umbilical cord plasma proteins revitalize hippocampal function in aged mice.» Nature, 2017; 544(7651): 488-492. DOI: 10.1038/nature22067
- U.S. Food and Drug Administration. «Statement on infusions of young donor plasma» (February 2019). FDA press statement
- National Medical Research Center for Hematology, Moscow (successor to Bogdanov’s Institute of Blood Transfusion) — institutional history of the first transfusion institute.
- Association for the Advancement of Blood and Biotherapies (AABB) — history and safety standards of transfusion medicine.
- PubMed: heterochronic parabiosis and circulating rejuvenation factors — primary literature on young-plasma research.